Even though the net position and cash burn will reduce this quarter and more importantly in FY17, one needs to take into account that the savings will be partly offset by expenditure on the Phase III HF trial that was previously funded by Teva.
This isn't a hidden fact. Its MSB resuming control of the HF trial and its own destiny.
Thats the bigger picture!
- Forums
- ASX - By Stock
- MSB
- Appendix 4C
Appendix 4C
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.47 |
Change
-0.040(2.65%) |
Mkt cap ! $1.667B |
Open | High | Low | Value | Volume |
$1.45 | $1.48 | $1.45 | $2.647M | 1.812M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 26969 | $1.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.47 | 37745 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1400 | 1.465 |
7 | 57957 | 1.460 |
9 | 104994 | 1.455 |
20 | 201469 | 1.450 |
9 | 95896 | 1.445 |
Price($) | Vol. | No. |
---|---|---|
1.470 | 21618 | 8 |
1.475 | 18482 | 6 |
1.480 | 65763 | 9 |
1.485 | 62025 | 5 |
1.490 | 46190 | 6 |
Last trade - 11.19am 08/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |